NovaBridge's VIS-101 Phase 2a Wet AMD Study Delivers Strong Positive Results, Signaling Best-in-Class Durability
summarizeSummary
NovaBridge Biosciences and its subsidiary Visara announced positive topline results from their Phase 2a study of VIS-101 for wet age-related macular degeneration (wet AMD). The study demonstrated rapid, robust, and durable treatment responses, with mean improvement in Best Corrected Visual Acuity (BCVA) of over 10 ETDRS letters and median central subfield thickness (CST) reduction of 100-150 mm. This announcement follows NovaBridge's 6-K filing on March 3, 2026, which stated the company would host a virtual business update call on March 9 to review Phase 2a clinical data, making these the anticipated results. The data indicates potential best-in-class durability, with approximately two-thirds of patients retreatment-free at 4 months and half at 6 months, alongside a favorable safety profile. For a small-cap biotech company, positive Phase 2a results for a drug targeting a significant market like wet AMD are a major de-risking event and a strong validation of its pipeline, significantly enhancing its value proposition. The company plans to initiate a dose-determining Phase 2b study in the second half of this year, followed by a global Phase 3 program in 2027, which will be critical next catalysts.
At the time of this announcement, NBP was trading at $3.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $403.5M. The 52-week trading range was $0.60 to $6.79. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.